Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
31
0

Year Published

2011
2011
2018
2018

Publication Types

Select...
7

Relationship

5
2

Authors

Journals

citations
Cited by 37 publications
(31 citation statements)
references
References 47 publications
0
31
0
Order By: Relevance
“…18,19 This was a multicentre study that randomized patients with proximal or mid-left anterior descending artery occlusion in a 2×2 factorial design to bolus intracoronary abciximab vs. no abciximab and to manual aspiration thrombectomy vs. no thrombectomy. All patients received aspirin, clopidogrel, or prasugrel, and bivalirudin during the procedure.…”
Section: Methodsmentioning
confidence: 99%
“…18,19 This was a multicentre study that randomized patients with proximal or mid-left anterior descending artery occlusion in a 2×2 factorial design to bolus intracoronary abciximab vs. no abciximab and to manual aspiration thrombectomy vs. no thrombectomy. All patients received aspirin, clopidogrel, or prasugrel, and bivalirudin during the procedure.…”
Section: Methodsmentioning
confidence: 99%
“…As previously described, 19 INFUSE-AMI was an open-label, 2×2 factorial, prospective, randomized, multicenter, single-blind trial of bolus intralesional abciximab administration and manual thrombus aspiration in patients undergoing primary PCI for anterior STEMI. Patients aged ≥18 years with ≥1 mm of ST-segment-elevation in ≥2 contiguous leads in V1 through V4 or new left bundle branch block with anticipated symptom onset to device time of ≤5 hours were enrolled.…”
Section: Protocol and Patientsmentioning
confidence: 99%
“…18 To overcome these limitations, we performed the INFUSE-AMI trial, in which 452 patients presenting early with STEMI because of an occluded proximal or mid left anterior descending (LAD) coronary artery were randomized before PCI to intralesional delivery of a bolus dose of abciximab versus no abciximab and to thrombus aspiration versus no aspiration. 19 All patients received bivalirudin without a postprocedural abciximab infusion to minimize bleeding and improve survival. 20,21 As previously reported, the 30-day infarct size primary end point, as assessed by cardiac MRI (CMRI), was reduced by intralesional abciximab but not by thrombus aspiration.…”
Section: Circ Cardiovasc Intervmentioning
confidence: 99%
See 2 more Smart Citations